Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: Watches Of Switzerland Ticks Along Nicely

Thu, 13th Aug 2020 09:00

(Alliance News) - Stock prices in London opened lower on Thursday with a raft of shares going ex-dividend weighing on the FTSE 100, while a stalemate in Congress over US economic stimulus was eroding investor sentiment.

In London, early Thursday, the blue-chip FTSE 100 index was down 66.72 points, or 1.1%, at 6,213.41. The mid-cap FTSE 250 index was down 102.88 points, or 0.7% at 17,987.50. The AIM All-Share index was up 0.2% at 956.87.

The Cboe UK 100 index was down 1.2% at 618.69. The Cboe 250 was down 0.5% at 15,365.68, and the Cboe Small Companies was flat at 9,445.65.

In mainland Europe, the CAC 40 index in Paris was down 0.2%, while the DAX 30 in Frankfurt was down 0.1%.

In the FTSE 100, GVC Holdings was up 0.2% after the gambling firm said the resumption of sporting events and reopening of betting shops leave it well placed for the rest of the year.

For the half-year ended June 30, net gaming revenue was down 11% to GBP1.61 billion from GBP1.81 billion a year before, and underlying pretax profit was down 75% to GBP55.4 million from GBP212.1 million. On a reported basis, GVC swung to a pretax profit of GBP22.7 million from a GBP12.3 million loss a year before.

UK retail like-for-like net gaming revenue was down 50% to GBP277.9 million, which the company attributed to cancelled sporting events due to lockdown restrictions.

GVC scrapped its interim dividend, having paid out 17.6 pence last year, citing uncertainty brought about by Covid-19.

"The company has been busy in adapting to pandemic challenges, with the cancellation of the dividend, a suspension in marketing spend and the access to additional liquidity if required. Government schemes and business rates relief were also a boon, leading to two outcomes which represent particular achievements. Not only did the company remain cash neutral throughout lockdown, but the profit after tax figure is flat in comparison with the corresponding period last year, which is notable given the circumstances," said Interactive Investor's Richard Hunter.

At the other end of the large-cap index, a slew of stocks went ex-dividend - meaning new buyers no longer qualify for the latest payout.

Phoenix Group was the worst FTSE 100 performer, down 4.0%. Legal & General was down 2.5%, Aviva, down 2.5% and GlaxoSmithKline was down 2.2%.

In the FTSE 250, Watches of Switzerland was the best performer, up 17% after the luxury timepiece retailer said it delivered a strong performance in its maiden year as a public company.

For the financial year ended April 26, revenue was up 6% to GBP819.3 million from GBP797.7 million in financial 2019, and adjusted pretax profit was GBP49.4 million, up 86% from GBP26.5 million.

For financial 2021, Watches of Switzerland expects revenue in a range between GBP840 million to GBP860 million, on the basis of a continued strong luxury watch market in the UK and US.

The company is the biggest retailer of Swiss watch Rolex in the UK and owns the Goldsmiths and Mappin & Webb jewellers.

At the other end of the midcaps, National Express was the worst performer, down 15% after the transport company said the onset of Covid-19 had an immediate and unprecedented effect on all of its transport businesses.

For the half-year ended June 30, revenue was GBP1.03 billion, down 23% from GBP1.34 billion last year, and the company swung to a pretax loss of GBP122.2 million, from a GBP88.4 million profit last year.

Looking ahead, given the uncertainty on the duration of Covid-19, National Express said it is not currently providing profit guidance for 2020.

Meanwhile, investors are hopeful that Congress will eventually agree on a new pandemic deal despite long-running animosity between Democrats and Republicans.

However, both sides are blaming each other for the lack of progress, with Treasury Secretary Steven Mnuchin saying House Leader Nancy Pelosi would not budge unless the Democrats' demand for spending of at least USD2 trillion is met.

That is well down from the USD3.5 trillion initially proposed by Democrats but Republicans say they are unwilling to shift from their USD1 trillion plan.

"Perhaps more concerning are the 16 million jobless Americans who are longing for the next stimulus package to be passed in Congress as the stalemate continues between the Democrats and Republicans. Failure for a deal to be reached could undermine the US economic recovery. Whilst the two sides are expected to eventually cross the line, timing is everything. The longer it takes the more damage to the economy. The US dollar is back under pressure after two straight days of gains," City Index analyst Fiona Cincotta noted.

The latest US initial jobless claims figures are out Thursday at 1330 BST.

The pound was quoted at USD1.3070 Thursday morning, up from USD1.3044 Wednesday's equities close in London.

The euro was priced at USD1.1814, up from USD1.1794. Against the yen, the dollar was quoted at JPY106.70, soft from JPY106.94 in London.

Brent oil was trading at USD45.34 a barrel Thursday morning, firm from USD45.26 a barrel Wednesday evening.

Gold was quoted at USD1,931.52 an ounce, lower from USD1,948.50 an ounce at the close Wednesday.

The Japanese Nikkei 225 index closed up 1.8%. In China, the Shanghai Composite ended flat, while the Hang Seng index in Hong Kong is down 0.2%.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.